Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB
Introduction: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB). Methodology: Patients diagnosed with pneumonia caused by CR-GNB and adm...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Journal of Infection in Developing Countries
2024-07-01
|
| Series: | Journal of Infection in Developing Countries |
| Subjects: | |
| Online Access: | https://jidc.org/index.php/journal/article/view/18887 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193633146306560 |
|---|---|
| author | Di Liu Fang Jie Yongjie Ding Hongping Qu Dechang Chen Jie Huang |
| author_facet | Di Liu Fang Jie Yongjie Ding Hongping Qu Dechang Chen Jie Huang |
| author_sort | Di Liu |
| collection | DOAJ |
| description |
Introduction: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB).
Methodology: Patients diagnosed with pneumonia caused by CR-GNB and admitted to the intensive care unit (ICU) from January 2020 to September 2022 were enrolled in this study. The patients were divided into the CS group and the PMB group according to their medication regimens. Group-wise demographic data, clinical efficacy, prognosis, and adverse events were analyzed and compared.
Results: A total of 120 patients (68 in the CS group and 52 in the PMB group) with pneumonia were included in the study. The majority of the pathogens were CR-Acinetobacter baumannii, followed by CR-Klebsiella pneumoniae, and CR-Pseudomonas aeruginosa. The clinical response rates in the CS and PMB groups after treatment were 62.0% and 65.4%, bacterial clearances were 44.0% and 36.5%, 28-day mortality rates were 16.0% and 13.5%, respectively; no significant differences between the two treatments were found. Nevertheless, the adverse effects were significantly less common in the CS group than in the PMB group, especially when treatments were administered intravenously.
Conclusions: CS, a novel polymyxin E formulation, is as effective as PMB in treating pneumonia induced by CR-GNB while causing less side effects.
|
| format | Article |
| id | doaj-art-e2789373198a4739b7914d4bf5e89f04 |
| institution | OA Journals |
| issn | 1972-2680 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | The Journal of Infection in Developing Countries |
| record_format | Article |
| series | Journal of Infection in Developing Countries |
| spelling | doaj-art-e2789373198a4739b7914d4bf5e89f042025-08-20T02:14:11ZengThe Journal of Infection in Developing CountriesJournal of Infection in Developing Countries1972-26802024-07-01180710.3855/jidc.18887Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNBDi Liu0Fang Jie1Yongjie Ding2Hongping Qu3Dechang Chen4Jie Huang5Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China Department of Pharmacy, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China Department of Respiratory and Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, ChinaDepartment of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China Department of Critical Care Medicine, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China Introduction: The aim of this study was to compare the efficacy and safety of colistin sulfate (CS) with polymyxin B sulfate (PMB) in the treatment of pneumonia induced by carbapenem-resistant Gram-negative bacteria (CR-GNB). Methodology: Patients diagnosed with pneumonia caused by CR-GNB and admitted to the intensive care unit (ICU) from January 2020 to September 2022 were enrolled in this study. The patients were divided into the CS group and the PMB group according to their medication regimens. Group-wise demographic data, clinical efficacy, prognosis, and adverse events were analyzed and compared. Results: A total of 120 patients (68 in the CS group and 52 in the PMB group) with pneumonia were included in the study. The majority of the pathogens were CR-Acinetobacter baumannii, followed by CR-Klebsiella pneumoniae, and CR-Pseudomonas aeruginosa. The clinical response rates in the CS and PMB groups after treatment were 62.0% and 65.4%, bacterial clearances were 44.0% and 36.5%, 28-day mortality rates were 16.0% and 13.5%, respectively; no significant differences between the two treatments were found. Nevertheless, the adverse effects were significantly less common in the CS group than in the PMB group, especially when treatments were administered intravenously. Conclusions: CS, a novel polymyxin E formulation, is as effective as PMB in treating pneumonia induced by CR-GNB while causing less side effects. https://jidc.org/index.php/journal/article/view/18887polymyxincolistin sulfatepolymyxin B sulfatecarbapenem-resistant Gram-negative bacteriapneumonia |
| spellingShingle | Di Liu Fang Jie Yongjie Ding Hongping Qu Dechang Chen Jie Huang Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB Journal of Infection in Developing Countries polymyxin colistin sulfate polymyxin B sulfate carbapenem-resistant Gram-negative bacteria pneumonia |
| title | Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB |
| title_full | Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB |
| title_fullStr | Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB |
| title_full_unstemmed | Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB |
| title_short | Real-world data on the effects of colistin sulfate and polymyxin B sulfate in the treatment of pneumonia induced by CR-GNB |
| title_sort | real world data on the effects of colistin sulfate and polymyxin b sulfate in the treatment of pneumonia induced by cr gnb |
| topic | polymyxin colistin sulfate polymyxin B sulfate carbapenem-resistant Gram-negative bacteria pneumonia |
| url | https://jidc.org/index.php/journal/article/view/18887 |
| work_keys_str_mv | AT diliu realworlddataontheeffectsofcolistinsulfateandpolymyxinbsulfateinthetreatmentofpneumoniainducedbycrgnb AT fangjie realworlddataontheeffectsofcolistinsulfateandpolymyxinbsulfateinthetreatmentofpneumoniainducedbycrgnb AT yongjieding realworlddataontheeffectsofcolistinsulfateandpolymyxinbsulfateinthetreatmentofpneumoniainducedbycrgnb AT hongpingqu realworlddataontheeffectsofcolistinsulfateandpolymyxinbsulfateinthetreatmentofpneumoniainducedbycrgnb AT dechangchen realworlddataontheeffectsofcolistinsulfateandpolymyxinbsulfateinthetreatmentofpneumoniainducedbycrgnb AT jiehuang realworlddataontheeffectsofcolistinsulfateandpolymyxinbsulfateinthetreatmentofpneumoniainducedbycrgnb |